It is widely accepted that one shortcoming of microarray prognosis experiments is the low reproducibility.
We found that the gene set from Abba et al was already reduced from 300 to 46 genes using eight prognosis experiments.
On the other hand, an association between a gene signature derived from laboratory experiments and the prognosis of breast cancer patients does not necessarily imply that the genes which compose a given signature are of biological significance to the disease.
The feasibility and benefits of this new prognosis process is investigated with an experiment using a manufacturing TELMA (TELe-MAintenance) platform supporting the unwinding of metal bobbins.
It is an experiment with a positive prognosis and little potential downside.
Following a literature search of the most important microarray experiments relating to breast cancer prognosis, 250 candidate genes were selected.
We are optimistic that the quantitative ER pathway data generated by microarray experiments will better predict patient prognosis and clinical response to anti-estrogen therapy.
For Steinman, the prognosis offered the opportunity to run one last experiment.
Numerous cancer studies have combined gene expression experiments and clinical survival data to predict the prognosis of patients of specific gene types.
A computer experiment is presented which illustrates the possibility of a suggested prognosis procedure.
